XNK Therapeutics to present at Redeye Regenerative Medicine/Cell Therapy event

XNK's presentation will be followed by a short Q&A session. XNK's presentation will be followed by a short Q&A session. For more information, please contact: Johan Liwing, CEO, XNK TherapeuticsTel: +46 706 70 36 75  E-mail:johan.liwing@xnktherapeutics.com   About XNK Therapeutics AB XNK Therapeutics is a clinical stage immunotherapy company focused on bringing new and more effective treatments to cancer patients. The company is at the forefront of autologous NK cell-based...
Comunicato Precedente

next
Comunicato Successivo

next
Preferisci Informazione.News su Google

XNK's presentation will be followed by a short Q&A session.

For more information, please contact:
Johan Liwing, CEO, XNK Therapeutics
Tel: +46 706 70 36 75 
E-mail: johan.liwing@xnktherapeutics.com 

About XNK Therapeutics AB

XNK Therapeutics is a clinical stage immunotherapy company focused on bringing new and more effective treatments to cancer patients. The company is at the forefront of autologous NK cell-based cell therapy development with a proprietary technology platform and a pipeline spanning both hematological malignancies and solid tumor indications. The most advanced product, evencaleucel, is in phase II studies in combination with the CD38 antibody isatuximab targeting multiple myeloma. Other programs include XNK02 in acute myeloid leukemia, currently in preclinical studies in collaboration with MD Anderson Cancer Center and the Karolinska University Hospital, XNK03 in bladder cancer, currently in preclinical studies in collaboration with the Karolinska University Hospital and XNK04 in liver cancer in collaboration with a global pharma company. XNK's efforts are supported by a dedicated team that includes world-renowned NK cell experts and an approved in-house GMP facility. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.

The following files are available for download:

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/xnk-therapeutics-to-present-at-redeye-regenerative-medicinecell-therapy-event-302057229.html

Ufficio Stampa

 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom

Allegati
Slide ShowSlide Show
Non disponibili
;